🇺🇸

US SEC Filing Intelligence

· daily

General Federal Contracts — April 22, 2026

Four civilian government contracts totaling $395,776,263 in obligations highlight bullish IT services momentum across Department of the Interior, Veterans Affairs, Agriculture, and NASA, with zero defense exposure. Highest-materiality awards to MAXIMUS FEDERAL CONSULTING, LLC ($106M) and COGNOSANTE MVH LLC ($104M) under full and open competition signal durable revenue for custom programming and cloud operations through 2026. Palantir Technologies Inc. secures a $95M firm-fixed-price BPA for USDA farm IT systems, while California Institute of Technology's $91M NASA R&D award remains neutral due to its nonprofit status. Key watch item: progress on option exercises and outlays, as only partial funds are disbursed in three contracts.

4 total filings
· daily

All NASA Contracts — April 22, 2026

NASA dominates this $90,812,821 total obligation period with a single civilian contract (0/1 defense-related), focused on long-term space science R&D. The sole award to California Institute of Technology, a nonprofit, for the MAIA Multi-Angle Imager for Aerosols project carries a neutral signal (avg strength 4.0/10, materiality 3/10) with $60,980,603 already outlayed toward a $101,500,658 ceiling. Highest-conviction signal is low-risk multi-year funding continuity through 2028 for civilian space applications under NAICS 541715. Limited direct equity implications due to nonprofit recipient. Key watch item: outlay progress beyond $60,980,603 and exercise of options to reach full $101.5M value.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 22, 2026

The 21 filings for USA S&P 500 Technology reveal strong revenue momentum in core tech names, with semiconductors and software leaders like Lam Research (+24% YoY Q3 revenue to $5.84B), ServiceNow (+22% YoY subscription revenue to $3.671B), Texas Instruments (+19% YoY Q1 revenue to $4.83B), and Intuitive Surgical (+23% YoY Q1 revenue to $2.771B) driving sector outperformance amid 9-24% YoY growth averages; IBM added 9% YoY revenue with 100bps margin expansion to 56.2%. Institutional 13F filings (Arcadia, Chemung, Madison, Muirfield) underscore conviction in mega-caps, with NVDA, AVGO, AAPL, MSFT topping portfolios (e.g., Arcadia NVDA $30.8M, Broadcom $40.9M). Capital allocation trends favor shareholders via aggressive buybacks (Intuitive $1.123B Q1, ServiceNow 20.1M shares, Mueller $75M) and dividend hikes (IBM to $1.69/share, Century 10% to $0.32). Forward guidance is mostly raised (ServiceNow FY sub rev to $15.735-15.775B +22%, IBM FY >5% CC growth), though mixed with headwinds like Middle East delays (-75bps for ServiceNow). Non-tech outliers (banks, homebuilders, health) show mixed results but lag tech growth; overall, semis/software portfolio trend signals bullish rotation with Q2 catalysts ahead.

5 high priority 16 medium 21 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 22, 2026

Across 20 filings from NASDAQ-100 constituents and related entities, key themes include robust revenue growth in semiconductors (TI +19% YoY, Lam +24% YoY, Intuitive +23% YoY) contrasting with softness in homebuilding (Century -12.6% YoY) and healthcare (CHS -6.1% YoY), while Tesla showed +16% revenue amid AI advancements. Period-over-period trends reveal 6/10 earnings reporters with YoY revenue growth averaging +18%, but mixed margins (Tesla +478bp expansion vs. others flat/compressed) and strong free cash flow generation (Tesla +117%, TI FCF +154% TTM). Capital allocation remains shareholder-friendly with buybacks (Intuitive $1.12B, Century $40M, Mueller $75M, Pineapple expansion to $15M) and dividend hikes (Century +10%, TI +4% TTM), alongside 13F snapshots confirming institutional overweight in mega-caps like NVDA, AAPL, MSFT. Positive catalysts include Robotaxi launches (Tesla), Nasdaq uplisting (First Northern), and ETF splits, but risks from inventory builds (Tesla +23% days), guidance cuts (Century FY deliveries 9.5-10.5K), and reverse splits (Creative Media). Overall, semis outperform with upward guidance, signaling portfolio rotation opportunities into tech amid broader mixed sentiment.

4 high priority 16 medium 20 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 22, 2026

The 50 filings reveal a diverse snapshot dominated by ~25 neutral 13F-HR disclosures from investment managers showing heavy ETF allocations (Vanguard, Dimensional, iShares dominant in 90%+ of portfolios), with consistent overweight in tech giants (Apple/NVDA/MSFT top holdings across 20+ filers, e.g., $50M+ Apple in several) signaling broad conviction in US equities amid low active management. Q1 2026 earnings mixed: robust growth in Vertiv (+30% YoY sales, +430bps margins), Monarch Casino (+8.9% rev, +38.9% net income), but pressures in Otis (margins -130bps YoY) and Elevance Health (+1.5% rev but -34% op gain, Medicare -15.8% memberships). Financials highlights include Elevance raising FY adj EPS to >=$26.75 with $5.6B buyback auth and $1.72 div, First Northern Nasdaq uplisting Apr24, robust capital returns (Otis $400M repurchases, Monarch $17.6M shares). M&A active with National Healthcare $560M accretive acquisition (Q3 close), SPAC deals/terminations, HIVE $100M notes for capex. Forward guidance mostly raised (Vertiv FY sales +29-31% org, Otis low-mid single digits org), backlog builds (Otis mod +30%), but China weakness and costs persistent. Portfolio-level: avg rev growth ~15% YoY in reporters, margins mixed (-100bps avg compression), strong FCF enabling returns; implications favor resilient growth names amid macro caution.

10 high priority 40 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 22, 2026

Across 50 SEC filings primarily from Q1 2026 earnings and proxies (despite diverse sectors in the 'Consumer Staples' stream), overarching themes include mixed quarterly results with 12/20 earnings reporters showing YoY revenue growth averaging +10% (e.g., Philip Morris +9.1%, Stifel +18%, Moody's +8%) contrasted by sharp declines in cyclical names like Taylor Morrison (-28% home closings revenue) and Constellation Brands (-10.4% FY sales post-divestitures). Margin trends are bifurcated: expansions in Moody's (+150 bps to 53.2%), Teledyne (+60 bps non-GAAP to 22.6%), and Monarch (+ casino ops despite YoY dip), but compressions in Taylor Morrison (-420 bps gross) and Elevance Health (operating gain -34.2%). Capital allocation remains robust with buybacks/dividends in 10+ firms (e.g., Moody's $2.5B repurchase raise, Reliance $234M Q1 buybacks), signaling shareholder focus amid leverage stability (e.g., Kinder Morgan 3.6x Net Debt/EBITDA). Forward guidance shows resilience with raises in Teledyne (FY EPS +$1), Moody's repurchases, Philip Morris ($8.36-$8.51 EPS), and Elevance ($26.75+), building a catalyst calendar around Q2 earnings and AGMs. Portfolio-level patterns highlight outperformance in defensives like tobacco/beverages transitioning to smoke-free/high-margin beer, but underperformance in homebuilding/REITs; actionable now: favor buyback-heavy names with raised guidance over revenue decliners.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 22, 2026

Across 50 filings in the USA S&P 500 Industrials stream, Q1 2026 earnings dominate with major industrials (GE Vernova, Otis, Masco, Boeing) showing robust revenue growth averaging 13% YoY (GEV +16%, Otis +6%, Masco +6%, Boeing +14%), driven by services (+11% Otis, +6% GEV) and equipment, though segment weaknesses persist (GEV Wind -23% YoY, Otis New Equipment -5% organic). Backlogs expanded significantly (GEV +$13B seq to $163B, Otis Modernization +30% CC, Boeing record $695B), signaling multi-year visibility amid M&A (GEV Prolec $5.3B, Amneal Kashiv $750M cash/equity + milestones). Banks reported mixed NIM trends (expansions to 3.65% Stock Yards, compressions -7bps BankUnited) with strong capital returns ($1.4B GEV, $202M Masco buybacks; div hikes FS Bancorp 53rd consecutive). Guidance mostly raised/maintained (GEV rev $44.5-45.5B, Amneal EBITDA $740-770M), but sentiments mixed due to China weakness (Otis), tariffs/Wind losses (GEV). 13F snapshots reveal institutional conviction in industrials (United Rentals, Deere top Montgomery holdings; TransDigm Lynwood), while SPAC M&A (Archimedes/Forge Nano) adds tech-manufacturing alpha. Portfolio-level: 8/12 earnings reporters grew rev >5% YoY, buybacks/divs in 10/12 signal shareholder focus, but Wind/China drags cap upside.

6 high priority 44 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 22, 2026

Across the 5 filings in the USA S&P 500 Energy intelligence stream (with contextual non-energy inclusions), overarching themes include mixed financial performance highlighted by robust YoY earnings growth in Kinder Morgan (36% net income, 39% Adj NI) and Peapack-Gladstone (86% net income), contrasted by volume declines in energy transport and persistent cash burn in smaller entities like Hestia. Period-over-period trends show strong top-line expansion (Kinder Adj EBITDA +18% YoY, Peapack NII +32% YoY) but deteriorating operational metrics (Kinder refined volumes -2% YoY, crude -12% YoY; Hestia revenue flat at $0). Critical developments feature Kinder Morgan's $505M Monument Pipeline acquisition, 2% dividend hike to $0.2975/share, Moody's Baa1 upgrade, and flat 2026 net income guidance at $3.1B amid 2-5% adjusted growth; Stoke Therapeutics' proxy filings signal upcoming governance votes. Portfolio-level patterns reveal sector resilience in midstream energy via backlog growth ($10.1B, +$145M QoQ) and capital returns, but caution from asset-specific volume pressures and banking credit risks spilling into energy financing context. Market implications point to selective bullishness in pipelines with high utilization (90% in 2025 vs 74% 2016), tempered by flat outlooks and mixed sentiment (3/5 filings).

3 high priority 2 medium 5 total filings
· daily

US Material Events SEC 8-K Filings — April 22, 2026

Across 50 SEC filings from April 22, 2026, dominant themes include aggressive M&A and divestitures in healthcare/pharma (e.g., Amneal's $1.1B biosimilars deal, Certara's $135M sale, NHC's $560M acquisition), positive financings extending runways (TuHURA $50M, HIVE $100M notes), and frequent leadership transitions (17 filings, mostly neutral/positive like Best Buy and lululemon CEO successions). Period-over-period trends show robust revenue growth averaging +20% YoY in reporting firms (e.g., ServiceNow +22%, Medpace +26.5%, Goosehead +23%), margin expansions in specialties (Amneal +750bps), but pockets of compression (Medpace net margin -300bps YoY) and volume declines (Kinder Morgan crude -12% YoY). Guidance raises in 5/50 (Amneal EBITDA to $740-770M, ServiceNow subs to $15.7B) signal confidence, while SPAC terminations (Oak Woods, Plus Automation) and extensions highlight M&A volatility. Capital allocation leans shareholder-friendly with buybacks (Goosehead $49.8M, ServiceNow 20.1M shares) and dividend hikes (Kinder Morgan +2%). Sector patterns favor biotech/healthtech growth amid biosimilars LOE opportunities ($300B+), but mixed sentiments (12/50) flag execution risks in integrations and approvals.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 22, 2026

Across 50 filings from Dow Jones 30-related streams, Q1 2026 results reveal mixed performance in banking with net income up 5-24% YoY on average but QoQ flat/down amid NIM fluctuations (e.g., +55bps YoY at Colony to -12bps at Bankwell) and deposit shifts; industrials shine with revenue surges of 15-30% YoY (Vertiv +30%, GE Vernova +16%, TE Connectivity +15%) driven by AI/power demand, though Wind segments lag. Biotech catalysts emerge with Kyverna's positive trial data in gMG/SPS, while SPACs like NewHold IV complete $201M IPOs and First Northern uplists to Nasdaq. Capital returns strong with dividends (e.g., FS Bancorp 53rd consecutive, BankUnited +6%) and buybacks ($60M at BankUnited, $1.4B at GE Vernova); 13F-HR filings (20+) show institutional tilt to tech giants (Apple, Nvidia, Microsoft), gold ETFs, and broad indices amid neutral sentiment. Guidance raises in industrials/healthcare (Vertiv to $13.5-14B sales, Elevance EPS $26.75+) signal resilience, but consumer loan declines (-2-4% QoQ) and operating losses flag risks. Portfolio-level: 6/10 banks mixed sentiment, 4/5 industrials positive/mixed with backlog growth, proxy-heavy governance routine.

10 high priority 40 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 22, 2026

The April 22, 2026, US SEC filings digest reveals a quiet trading day dominated by 30+ 13F-HR reports from institutional managers, signaling sustained conviction in broad-market ETFs (Vanguard, Dimensional, iShares), tech giants (NVDA, AAPL, MSFT averaging 20-30% portfolio weights across filers), and value/small-cap tilts, with total AUM exceeding $10B in disclosed holdings. Q1 2026 earnings from Otis, Elevance, Vertiv, and Monarch highlight divergent industrials/healthcare trends: aggregate revenue growth of +11.6% YoY (Vertiv +30%, Otis +6%, Monarch +8.9%, Elevance +1.5%) but mixed margins (Vertiv +430bps outlier vs Otis -130bps, Elevance operating gain -34%). Positive catalysts include HIVE's $100M notes upsizing for GPU expansion, National Healthcare's $560M accretive M&A, Kyverna's positive trial data, and First Northern's Nasdaq uplisting; offsets include Otis China weakness, Gaotu persistent losses, Oak Woods SPAC merger termination, and CDT dilution risks. Capital allocation remains shareholder-friendly with $400M Otis buybacks, Monarch's $17.6M repurchases + $0.30 div, Elevance's $5.6B auth remaining + $1.72 div. Forward guidance leans constructive (Vertiv/Elevance raises), building a catalyst calendar around Q2 earnings, June dividends/meetings, and Q3 M&A closes. Portfolio implications: Overweight data center/AI enablers (Vertiv/HIVE) and healthcare operators amid resilient service growth; monitor industrials for China exposure.

11 high priority 39 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 22, 2026

Across 50 filings in the USA S&P 500 Consumer Discretionary stream (despite heavy financials/banks skew), Q1 2026 bank results dominate with mixed outcomes: 5/7 banks showed reported net income declines QoQ (avg -20%) due to merger costs/MTM losses but adjusted EPS often up YoY (e.g., First Merchants +9.6%, Pinnacle +26%), loans/deposits surged post-M&A (Pinnacle +118%/+111% LQ). Consumer discretionary pure-plays like Ulta Beauty (DEF 14A/DEFA14A) emphasize governance upgrades ahead of June 9 AGM, Winmark AGM >97% approvals. 30+ 13F-HRs reveal institutional conviction in tech/consumer names (Apple top in 15/30, avg $5-12M positions; Walmart heavy in MFA/Churchill), gold ETFs (Fulcrum/SPDR top), and broad ETFs, with no major shifts. Forward guidance bullish from Boston Scientific (FY26 organic sales 6.5-8%, Q2 5-7%). Capital allocation resilient: dividends maintained (FS Bancorp 53rd consecutive $0.29, Bankwell $0.20), Stifel 3:2 split. Risks include NIM compression (Bankwell -12bps), rising NPLs (Pinnacle 0.58%, Bankwell 0.66%), related-party debt (FreeCast $3.4M). Implications: M&A-driven growth but integration drags; monitor bank credit quality and Ulta vote outcomes for sector sentiment.

3 high priority 47 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 22, 2026

Across 50 filings in the USA S&P 500 Healthcare stream, Q1 2026 earnings show robust revenue growth in select areas like med devices (Boston Scientific +11.6% YoY) and financial services adjacent to healthcare (Stifel +18% YoY, CACI +8.5% YoY), but mixed results with pressures on margins (Bankwell NIM -12bps), operating gains (Elevance -34.2% YoY), and memberships (Medicare Advantage -15.8% YoY). Healthcare-specific filings highlight positive organizational shifts at Amgen for AI-driven R&D and non-dilutive funding at TuHURA extending runway to 2028, alongside biotech events like Spruce's public offering. Over 25 13F-HR filings from managers like Pinnacle Associates, AtlasMark, and Parcion reveal extreme concentration in tech megacaps (Nvidia top in 10+ portfolios, e.g., Ketron $124M) and ETFs, with minimal healthcare exposure (e.g., Biltmore $25.6M Health Care ETF outlier), signaling institutional derisking from sector amid volatility. Capital allocation trends favor dividends (Elevance $1.72 Q2, Civista +6% to $0.18) and buybacks (News Corp $1B program), while M&A integration challenges post-deals (Pinnacle loans +118% LQ but EPS -50% YoY) dominate financials. Forward guidance largely raised (CACI rev to $9.5-9.6B, Elevance EPS $26.75+), building a catalyst calendar into Q2-Q3 2026. Portfolio-level, 7/12 earnings reporters posted YoY revenue growth averaging +20%, but 5 showed margin/NIM compression averaging -20bps, implying selective opportunities in growth outperformers.

6 high priority 44 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 22, 2026

Across 50 DEF 14A proxy statements filed on April 22, 2026, for US SEC-listed firms, overarching themes include routine approvals for director elections, auditor ratifications, and advisory say-on-pay votes ahead of virtual AGMs clustered in May-June 2026, with 80% recommending annual pay frequency. Where enriched data available (15/50 filings), period-over-period trends show robust revenue growth averaging +15% YoY (e.g., Veracyte +16%, LegalZoom +11%, Oscar Health 41% CAGR 2023-2025), margin expansions (LegalZoom adj EBITDA 23%), and deposit/asset growth (Western Alliance +16.3% deposits YoY), though outliers like SAIC (-3% revenue YoY) highlight sector headwinds. Governance enhancements dominate (e.g., board declassifications in Ulta, Veracyte; independent chairs in GXO), alongside equity-heavy comp (PSUs tied to revenue/TSR/rTSR in Resideo, Pulmonx, LegalZoom) aligning pay with performance. Capital allocation favors buybacks ($422M Western Alliance, $375M Keros) over dividends, signaling confidence; leadership transitions (e.g., Pulmonx CEO/CFO changes with severance/sign-ons) mix bullish growth with dilution risks from equity plan expansions (Cerus +10M shares). Portfolio-level patterns reveal biotech (20+ firms) vulnerability to program halts (Keros cibotercept discontinued) vs. tech/fintech outperformance (Robinhood assets doubled). Market implications: High say-on-pay approval potential boosts sentiment, but watch dilution and reverse splits (Offerpad 1:5-50, DocGo 1:5-10) for pressure.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 22, 2026

The IPO Pipeline stream reveals a diverse set of capital market activities on April 22, 2026, including a fresh SPAC IPO by BurTech Acquisition Corp II targeting $100M, biopharma consolidation via Gazelle Parent's S-4 mergers requiring $350M cash infusion, a regional bank merger between Arrow Financial and Adirondack Bancorp, and CytoDyn's equity shelf registration amid ongoing balance sheet updates through February 2026. Absent explicit YoY/QoQ financial trends across filings, biopharmas highlight persistent historical losses and future unprofitability, contrasting BurTech's clean $100M trust deposit structure. Positive sentiment for BurTech signals SPAC market revival, while mixed/neutral tones for others underscore execution risks in mergers and dilutions. Portfolio-level patterns show heavy reliance on M&A/de-SPAC for biotech/fintech growth, with no dividend/buyback activity noted. Critical implications include near-term Nasdaq listings and stockholder votes as catalysts, favoring tactical plays in SPACs over risky biopharma combos.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — April 22, 2026

The 50 filings reveal a surge in SPAC activity with 7 new S-1/S-1A registrations (BurTech, RRE, ARC, etc.) signaling renewed blank-check IPO momentum amid favorable market conditions, alongside robust M&A in pharma (Amneal's $1.1B Kashiv deal) and healthcare real estate (NHC's $560M acquisition). Indian filings dominate insolvencies and open offers (9 cases including Kwality Walls 26% open offer at ₹21.33, AAA Tech 26% at ₹101), highlighting distress in real estate/infra but opportunistic takeovers. US period-over-period trends show revenue growth averaging +15% YoY across reporting firms (Gaotu +35%, GE Vernova +16%, Viomi +14.6%, LegalZoom +11%), but mixed profitability with op income declines (Viomi -17.8%) and net losses (Gaotu -$46M). Guidance raises (Amneal EBITDA to $740-770M, +3%) and capital returns (LegalZoom $80M cashback, GE Vernova $1.3B buybacks) bolster bullish signals, while regulatory penalties (Birla ₹4.6Cr) and SPAC terminations (Oak Woods, PlusAI) flag risks. Portfolio-level: Pharma/healthcare outperforms with synergies ($400-500M Amneal), contrasted by flat/declining metrics in Chinese tech (Yalla rev +0.7%). Critical implications: Monitor May-June AGMs/proxies for governance votes and Q4FY26 earnings boards (Bondada Apr27, Kajaria Apr30).

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 22, 2026

Across 36 Q1 2026 financial filings (mostly 10-Qs, some 10-Ks), revenue growth averaged ~10-15% YoY in high performers like GE Vernova (+16%), Vertiv (+30%), EQT (+94%), and Intuitive Surgical (+23%), but was mixed with declines in homebuilding (Taylor Morrison -27%), beverages (Constellation -10%), and healthcare services (Community Health -6%). Profitability showed stark contrasts: blowout net income surges (GE Vernova to $4.7B, EQT +515%) versus widening losses (Reborn Coffee -87%, KKR RE to $57M loss). Capital allocation leaned heavily toward aggressive buybacks totaling billions (e.g., Calix $172M, J&J $4B, Intuitive $1.1B) and acquisitions (GEV $4.9B, Boeing Spirit $8.4B, Wabtec $1.1B), signaling management conviction amid cash generation improvements in 20+ firms (e.g., United Airlines +29% op cash). Margin trends were pressured in 12/36 companies (avg -50-200bps compression from costs/investments), but industrials/energy outperformed with expansion. REITs faced credit/impairment hits (KKR +196% provisions), while airlines/industrials showed resilience. Portfolio implication: overweight growth industrials/energy on buybacks/M&A; trim cyclical decliners like housing/REITs ahead of potential slowdowns.

36 high priority 36 total filings
· daily

US SEC Trading Suspension Halt Orders — April 22, 2026

A surge of 8 small-cap companies across energy, biotech/pharma, technology, and real estate sectors received noncompliance notices from NYSE American (3) and Nasdaq (5) between April 16-20, 2026, primarily for failing to file 10-Ks for FY ended Dec 31, 2025, signaling systemic audit delays and financial reporting weaknesses among micro-caps. 7/8 filings cite late 10-Ks (Form 12b-25 filed March/April 2026), with one (Tevogen) failing market value rules ($50M MVLS, $15M MVPHS) and Vivos reporting negative equity of -$1.55M despite Q1 2026 $6.8M raise ($4.6M warrants + $2.25M placement). Sentiments are negative across 7/8 (mixed for Vivos), all 9/10 materiality, with cure periods clustered around October 12-15, 2026, after initial 60-180 day plans. No YoY/QoQ financial trends or insider activity reported, but operational highlights include EON's 1,000+ bopd from 750 Permian wells and La Rosa's Europe expansion. Delisting risks loom without assurances of compliance, pressuring listings and liquidity; Apimeds faces active trading halt since April 2. Portfolio implication: Avoid longs in these tickers, watch for suspensions amplifying volatility.

8 high priority 8 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 22, 2026

Across 37 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is widespread listing compliance distress, with 10+ companies (e.g., Vivos, Greenwave, Graf, Apimeds, BIO KEY, Tevogen, La Rosa, EON) receiving Nasdaq/NYSE notices for late 10-Ks, negative equity (-$1.55M at Vivos), or market value shortfalls ($50M MVLS/$15M MVPHS at Tevogen), signaling acute financial reporting and balance sheet pressures amid no bankruptcies but high delisting risks. Positive counter-trends include robust financings (e.g., HIVE $100M notes, TuHURA $50M credit, Firefly $8M units, Hepion $700K equity) and M&A/divestitures (Amneal $1.1B biosimilars deal, NHC $560M facilities, Certara $135M sale, Spire $75M divestiture) to extend runways and refocus operations. Period-over-period data shows mixed revenue growth: ServiceNow +22% YoY subscription revenues ($3,671M Q1), Amneal +4% YoY ($723M Q1) with +750bps gross margins to 44.3%, contrasting distress signals; guidance raised at Amneal (Adj EBITDA $740-770M FY26) and ServiceNow (subscription $15.735-15.775B FY26). Capital allocation leans toward debt/equity raises over returns, with ServiceNow repurchasing 20.1M shares. Portfolio-level patterns highlight small-cap biotech/healthcare (Spruce, TuHURA, Hepion) and tech (Greenwave, Tevogen) as distress hotspots, while larger caps like ServiceNow outperform; implications include short-term volatility from compliance deadlines (June-Oct 2026) and alpha in turnaround financings/M&A.

37 high priority 37 total filings
· daily

US Executive Officer Management Changes SEC — April 22, 2026

Across 34 SEC filings on USA Executive & Director Changes dated April 22, 2026, overarching themes include 10 annual shareholder meetings electing directors with mixed support levels (e.g., Equity Bancshares saw 30-40% opposition on some directors, while Seaboard and Citizens Financial passed overwhelmingly), smooth executive successions/retirements (12 cases, neutral sentiment), and strategic appointments in biotech/pharma (7 instances, positive). Period-over-period trends show robust Q1 2026 growth in select firms: Goosehead Insurance revenues +23% YoY to $93.1M, Medpace +26.5% to $706.6M, Kinder Morgan net income +36% YoY to $976M, NB Bancorp net income +95% QoQ to $15M, though offsets like Medpace backlog +2.9% QoQ and NB provision expense swing to $6.3M highlight margin risks. Critical developments: High-materiality CEO transitions at Best Buy (Jason Bonfig effective Oct 31, 2026) and Regal Rexnord (Aamir Paul by Jul 1, 2026) position growth continuity; PubMatic prelim Q1 rev $62.4M beat guidance. Portfolio-level patterns reveal biotech hiring expertise for pipelines (Vanda, Barinthus, Tenax), energy/transport volume declines (Kinder Morgan crude -12% YoY), and capital returns via dividends (Kinder +2%, NB $0.07/share) amid neutral insider conviction from retirements without sales.

33 high priority 1 medium 34 total filings